Tylvalosin (tartrate)

SKU HY-128423-10mM/1mL Category Tags , ,

$55$61

Products Details

Product Description

– Tylvalosin tartrate (Acetylisovaleryltylosin tartrate) is a macrolide antibiotic that can against Gram-positive bacteria[1][2].

Web ID

– HY-128423

Storage Temperature

– -20°C (Powder, stored under nitrogen)

Shipping

– Blue Ice

Applications

– COVID-19-immunoregulation

Molecular Formula

– C57H93NO25

References

– [1]Feng-yu Deng, et al. Characterization of the Interaction between Acetylisovaleryltylosin Tartrat and Bovine Serum Albumin without or with Zn2+ and Cu2+ by Spectroscopic Analysis. Guang Pu Xue Yu Guang Pu Fen Xi. 2016 Jul;36(7):2351-7.|[2]R Okamoto, et al. The activity of 4”-acylated tylosin derivatives against macrolide-resistant gram-positive bacteria. J Antibiot (Tokyo). 1979 May;32(5):542-4.

CAS Number

– 63428-13-7

Molecular Weight

– 1192.34

Compound Purity

– 98.77

SMILES

– OC([C@H](O)[C@@H](O)C(O)=O)=O.O[C@@H]1[C@@H](C)O[C@@H](OC[C@H]([C@@H](CC)OC(C[C@@H](OC(C)=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H](OC(CC(C)C)=O)[C@@](O)(C)C3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@H]4C)=O)/C=C(C)/C=C/C4=O)[C@H](OC)[C@@H]1OC

Clinical Information

– No Development Reported

Research Area

– Infection

Solubility

– DMSO : 100 mg/mL (ultrasonic)

Target

– Antibiotic;Bacterial

Isoform

– Macrolide

Pathway

– Anti-infection

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=